Tempus Ai, Inc. (TEM) Stock Price & Analysis
Tempus Ai, Inc. (TEM) fell 7.22% to USD 42.69 as of July 25, 2026 at 02:21 UTC, according to Nexqual real-time market data.
TEM last closed at USD 46.01; the session ranged USD 42.66–46.42 on volume of 5,636,748 shares. Market capitalization is $7.69B, with a 52-week range of USD 41.73–104.32 (NMS). Source: Nexqual, July 25, 2026 at 02:21 UTC.
Key Statistics (as of July 25, 2026 at 02:21 UTC)
| Price | USD 42.69 |
|---|---|
| Change | ▼ 7.22% (down) |
| Previous Close | USD 46.01 |
| Open | USD 46.25 |
| Day Range | USD 42.66 – 46.42 |
| 52-Week Range | USD 41.73 – 104.32 |
| Volume | 5,636,748 shares |
| Market Cap | $7.69B |
| Exchange | NMS |
Technical Analysis (TEM)
Nexqual's technical model rates TEM "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 02:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.95 (neutral) |
| vs SMA50 | Below (USD 51.21) |
| MACD | -1.78 (negative) |
Analyst Ratings (TEM)
Wall Street analysts rate TEM "Buy" based on 14 analysts, with a mean price target of USD 66.57 (range USD 35–100), per Nexqual as of July 25, 2026 at 02:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 66.57 |
| High Target | USD 100 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 8 / 7 / 1 |
Earnings (TEM)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.15 |
| Revenue Estimate | $379.54M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.05 ▲ beat |
| 2025-09-30 | USD -0.11 vs est -0.18 ▲ beat |
| 2025-06-30 | USD -0.22 vs est -0.25 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financials & Fundamentals (TEM)
| Total Revenue | $1.36B |
|---|---|
| Revenue Growth (YoY) | +36.10% |
| Gross Margin | +63.39% |
| Operating Margin | -24.33% |
| Profit Margin | -22.20% |
| ROE | -81.58% |
| Debt / Equity | 316.65 |
| Current Ratio | 3.32 |
| Total Cash | $639.07M |
| Total Debt | $1.32B |
| Free Cash Flow | $-55.76M |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Financial Health Score (TEM)
Nexqual rates Tempus Ai, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:21 UTC.
| Growth | Strong — Revenue +83% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 63%, operating -24% |
| Balance Sheet | Weak — $639M cash vs $1.32B debt |
| Cash Flow | Weak — FCF negative: -$56M, burning cash |
| Efficiency | Critical — ROE -82%, ROA -9.1% |
Ownership (TEM)
| Insider Ownership | +36.98% |
|---|---|
| Institutional Ownership | +54.69% |
| Shares Outstanding | 175.02M |
| Float | 114.27M |
| Short % of Float | +33.94% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
Leadership (TEM)
Tempus Ai, Inc. is led by Eric P. Lefkofsky (age 55), Co-Founder, CEO, President & Chairman, per Nexqual as of July 25, 2026 at 02:21 UTC.
| Co-Founder, CEO, President & Chairman | Eric P. Lefkofsky (age 55) |
|---|---|
| Chief Financial Officer | James Rogers (age 38) |
| Chief Technology Officer | Shane Colley |
| Chief Scientific Officer | Kate A. Sasser (age 47) |
| Vice President of Investor Relations & Competitive Intelligence | Elizabeth Krutoholow |
Major Backers & Investors (TEM)
Notable institutional backers of Tempus Ai, Inc. include ARK Invest, Baillie Gifford, Softbank Group Corporation, according to Nexqual as of July 25, 2026 at 02:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 10.41% |
| Baillie Gifford | 4.96% |
| Softbank Group Corporation | 3.1% |
| JPMorgan | 2.83% |
| Sumitomo Mitsui Trust Group, Inc. | 2.48% |
| Amova Asset Management Americas Inc | 2.48% |
| UBS Group AG | 1.85% |
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 0.57% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.78% |
| BlackRock | 5.96% |
Source: Nexqual, July 25, 2026 at 02:21 UTC.
From Tempus Ai, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Tempus AI, Inc. operates as a healthcare technology company in the United States.
- It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests.
- The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.
- In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NBIS | Nebius Group N.V. | USD 187.77 | ▼ 13.93% |
| OKLO | Oklo Inc. | USD 40.25 | ▼ 9.55% |
| CRWV | CoreWeave, Inc. | USD 71.88 | ▼ 13.02% |
| VST | Vistra Corp. | USD 163.38 | ▼ 2.02% |
| HIMS | Hims & Hers Health, Inc. | USD 28.09 | ▼ 11.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:21 UTC. This page is informational and not investment advice.